Discontinued — last reported Q3 '24

Business Segments · Percent of Revenue Contributed

Drug Development — Percent of Revenue Contributed

Labcorp Holdings Drug Development — Percent of Revenue Contributed remained flat by 0.0% to 22.0% in Q3 2024 compared to the prior quarter. Year-over-year, this metric declined by 4.3%, from 23.0% to 22.0%.

Analysis

StatementSegment
CategoryMarket Position
SignalContext dependent
VolatilityStable
First reportedQ1 2016
Last reportedQ3 2024

How to read this metric

An increase suggests the company is becoming more reliant on pharmaceutical R&D spending, while a decrease indicates a greater focus on core clinical diagnostic testing.

Detailed definition

This metric represents the proportion of total consolidated revenue generated by the drug development and clinical resea...

Peer comparison

Similar to revenue mix metrics for diversified healthcare companies that operate both diagnostic labs and CRO services.

Metric ID: lh_segment_drug_development_percent_of_revenue_contributed

Historical Data

11 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24
Value39%36%37%39%39%37%23%23%22%22%22%
QoQ Change-7.7%+2.8%+5.4%+0.0%-5.1%-37.8%+0.0%-4.3%+0.0%+0.0%
YoY Change+0.0%+8.3%+0.0%-41.0%-41.0%-40.5%-4.3%-4.3%
Range22%39%
CAGR-20.5%
Avg YoY Growth-15.4%
Median YoY Growth-4.3%
Current Streak2 quarters growth

Frequently Asked Questions

What is Labcorp Holdings's drug development — percent of revenue contributed?
Labcorp Holdings (LH) reported drug development — percent of revenue contributed of 22.0% in Q3 2024.
How has Labcorp Holdings's drug development — percent of revenue contributed changed year-over-year?
Labcorp Holdings's drug development — percent of revenue contributed decreased by 4.3% year-over-year, from 23.0% to 22.0%.
What does drug development — percent of revenue contributed mean?
The percentage of total company revenue that comes from drug development and clinical research services.